NCT01787487View on ClinicalTrials.gov

Ruxolitinib Phosphate and Azacytidine in Treating Patients With Myelofibrosis or Myelodysplastic Syndrome/Myeloproliferative Neoplasm

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

121

Participants

Timeline

Start Date

March 13, 2013

Primary Completion Date

April 30, 2027

Study Completion Date

April 30, 2027

Conditions
Myelodysplastic/Myeloproliferative Neoplasm, UnclassifiableMyelofibrosis Transformation in Essential ThrombocythemiaPolycythemia Vera, Post-Polycythemic Myelofibrosis PhasePrimary Myelofibrosis
Interventions
DRUG

Azacitidine

Given SC or IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Ruxolitinib Phosphate

Given PO

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT01787487 - Ruxolitinib Phosphate and Azacytidine in Treating Patients With Myelofibrosis or Myelodysplastic Syndrome/Myeloproliferative Neoplasm | Biotech Hunter | Biotech Hunter